Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial–again
BioSpace
New Phase 3 data show that Summit Therapeutics and Akeso's PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck's Keytruda but the results will need
pharminent
September 3, 2026 (Last updated: September 7, 2026)
BioSpace
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need